Kindred Biosciences

Kindred Biosciences is a veterinary biotechnology company, focuses on developing therapies for dogs, cats, and horses. It develops canine, feline, and equine antibodies for the treatment of diseases in companion animals. Its strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. Their mission is to bring innovative biologics to veterinary medicine because they believe their pets deserve the same kinds of safe and effective medicines that human family members enjoy. The company was incorporated in 2012 and is based in San Francisco, California.

Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Kindred Biosciences (KIN) Q2 Earnings Expected to Decline

Covanta Holding Corp

Riverview Financial Corp

Southwestern Energy

NEW YORK, July 21, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY  10036 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Covanta Holding Corporation (NYSE: CVA) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Covanta Holding Corporation (NYSE: CVA) in connection with the proposed acquisition of the company by EQT Infrastructure.

SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations

Elanco Animal Health Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kindred Biosciences, Inc. (NasdaqGS: KIN) to Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the proposed transaction, shareholders of Kindred will receive only $9.25 for each share of Kindred that they own. KSF is seeking to determine whether this consideration and the process that led to i

KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN

NEW YORK, June 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kindred Biosciences, Inc. ("KIN" or the "Company") (KIN) relating to its proposed acquisition by Elanco Animal Health, Inc. KIN shareholders will receive $9.25 in cash per share they own. The investigation focuses on whether Kindred Biosciences, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN

The pet therapeutics pioneer is being scooped up by a global animal health leader.

Why Kindred Biosciences Stock Skyrocketed Today

Elanco Animal Health Inc (NYSE: ELAN) said on Wednesday it will acquire Kindred Biosciences Inc (NASDAQ: KIN) for roughly $440 million (£312 million) to expand its footprint in the pet health industry. The acquisition will bring three potential dermatology blockbusters, which are currently in the development phase, under Elanco's umbrella.

Kindred Biosciences to merge with Elanco Animal Health

Aprea Therapeutics

Catabasis Pharmaceuticals

Inhibikase Therapeutics

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kindred Biosciences, Inc. (NASDAQ: KIN) to Elanco Animal Health Incorporated for $9.25 per share is fair to Kindred Biosciences shareholders. Halper Sadeh encourages Kindred Biosciences shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The i

Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN

The stock price of Kindred Biosciences Inc (NASDAQ: KIN) increased by over 45% pre-market. This is why it happened.

KIN Stock Price Increases Over 45% Pre-Market: Why It Happened

Elanco Animal Health Incorporated (NYSE: ELAN) has agreed to acquire Kindred Biosciences Inc (NASDAQ: KIN) for $9.25 per share, or approximately $440 million. The price represents a premium of 52% based on the 30-day average.

Kindred Biosciences Stock Jumps On $440M Elanco Animal Buyout Deal

Elanco Animal Health Inc. said Wednesday it has entered an agreement to acquire Kindred Biosciences Inc. for about $440 million, adding three potential dermatology blockbusters to its pipeline. Under the terms of the deal, Elanco will pay $9.l254 a share for each Kindred share owned, equal to a 52% premium based on the 30-day average closing price.

Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket

GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

Elanco Announces Agreement to Acquire Kindred Biosciences

Kindred Bio (KIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?

SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group.

Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus

SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2021 Virtual Jaws & Paws Conference on June 2 and the LD Micro Invitational XI on June 8.   Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings.

Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI

Kindred Biosciences, Inc. (KIN) CEO Dr. Richard Chin on Q1 2021 Results - Earnings Call Transcript

Shares of Kindred Biosciences (NASDAQ:KIN) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 46.67% year over year to ($0.24), which were in line with the estimate of ($0.24).

Kindred Biosciences: Q1 Earnings Insights

SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of $2.4 million and a net loss of $9.7 million, or $0.24 per share.

Kindred Biosciences Announces First Quarter 2021 Financial Results

SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2021 financial results on May 11, 2021, after the market close. The Company will host a conference call at 4:30 p.m.

Kindred Biosciences to Announce First Quarter 2021 Financial Results

Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United States Department of Agriculture (USDA) Center for Veterinary Biologics has accepted efficacy data to support the prophylactic indication for KIND-030. The pivotal efficacy data demonstrated that 0% of the KIND-030 treated dogs developed parvovirus infection while 100% of the placebo-control dogs developed the disease, and also showed 100% survival rate in KIND-030.

Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab.

Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 9.31% stake in Kindred Biosciences Inc. (NASDAQ:KIN) earlier this week.

Steven Cohen Adopts Stake in Kindred Biosciences

Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2020 Results - Earnings Call Transcript

Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Kindred Biosciences Stock (KIN)